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CASE FINDING FOR PULMONARY TUBERCULOSIS AMONG PEOPLE WHO
INJECT DRUGS IN DAR ES SALAAM, TANZANIA. Akash Gupta. Jessie Mbwambo.
Ibrahim Mteza. Sheela Shenoi. Barrott Lambdin. Cassian Nyandindi. Basra Ismail Doula,
Said Mfaume, and Robert Douglas Bruce. Department of Internal Medicine, Yale
University, School of Medicine, New Haven, CT.
Active case finding is a World Health Organization (WHO)-endorsed strategy for
improving case detection of tuberculosis. Despite WHO recommendations for active case
finding among people who inject drugs (PWID), there are few published studies. The
historical focus of case finding has been in populations that are HIV-positive,
incarcerated, or at higher occupational risk. We sought to examine the yield of active case
finding among PWID newly started on methadone in Tanzania.
A questionnaire including tuberculosis symptoms and risk factors was
administered to every consenting patient by a native Swahili-speaker. Additional chart
review was performed for demographic information and HIV status. Two sputum
samples were collected for every symptomatic patient, and samples were tested using
smear microscopy as well as culture.
A total of 156 of 222 (70%) methadone clients met with study administrators; 150
of whom consented to the study. Median age was 34 years old, and 139 (93%) were male.
Thirty-four (23%) were HIV-positive, and an additional 104 (69%) had an unknown HIV
status. Of the 150 patients surveyed, 16 (11%) had one or more tuberculosis symptoms
and were referred for laboratory testing. Six new cases of tuberculosis were identified, 5
of which were sputum smear-negative, and 1 of which was multi-drug resistant. The
prevalence of tuberculosis was 4%
This study presents the first data on tuberculosis prevalence in a population of
PWID in Tanzania. This prevalence is 23 times the general Tanzanian tuberculosis
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prevalence of 0.2%. PWID in Tanzania should continue to be screened for tuberculosis
with smear, culture and drug susceptibility testing. Screening should expand to PWID in
the community.
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Introduction
History of Tuberculosis
Tuberculosis (TB) is a devastating infectious disease that has been infecting mankind for
many millennia. The oldest skeletal remains of a TB patient come from Liguria, Italy
around 5800 BCE.(1) The first written records come from ancient Egypt, where
physicians first described the disease.(2) Investigators have found DNA evidence of the
mycobacteria in Egyptian mummies buried between 2050 BC to 500 BC.(3) Hippocrates
in Greece labeled the disease “phthisis”(2), and the disease appears often in Western
literature as “consumption”(4). In 17th century London, the disease became so prevalent
and had such high mortality that the English preacher John Bunyan dubbed TB, “The
Captain among these men of death”.(5) The industrial revolution brought increasingly
crowded living conditions, drastically increasing TB transmission and incidence in
Europe.(2) In London, 1 in 7 deaths were caused by TB at the beginning of the 18th
century, 1 in 5.25 in the middle, and 1 in 4.2 by the end of the century.(6) TB caused 25%
of deaths in Europe in the 19th century(5). Despite this large societal burden, the
causative pathogen, Mycobacterium tuberculosis, was not discovered until 1882 by
Robert Koch in Germany.(2)

In the 20th century, the developed world saw improvements in the TB death toll due to
better living standards, including improved nutrition, income, and less crowded housing
conditions.(5) Additionally, antimicrobial treatment was developed in the 1940s with the
discovery of streptomycin, evolving into a multi-drug therapy regimen of several
different antibiotics, greatly improving treatment outcomes from the era of sanatorium
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and surgery-based care.(2) However, the advent of the HIV epidemic in the 1980s fueled
a resurgence of TB, especially in Sub-Saharan Africa. TB control efforts now face the
challenges of HIV/TB coinfection, drug-resistant organisms, inadequate diagnostic tests,
and weak health systems in the countries most affected.(5)

Disease Characteristics
It is now known that the disease can be caused by a group of bacteria known as the
Mycobacterium

tuberculosis

complex,

including

Mycobacterium

tuberculosis,

Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, and
Mycobacterium canetti. Before milk pasteurization became routine, Mycobacterium bovis
caused up to 6% of TB cases.(5) After the Mycobacteria infect a human, most
immunocompetent individuals either eliminate the bacteria or contain it in an inactive
state called latent TB infection (LTBI).(5) Active TB disease is most commonly caused
by reactivation of a latent infection, when the organism multiplies to cause pathology and
active, symptomatic disease.(7) In an immunocompetent host the lifetime risk of
reactivation is approximately 10%, with the greatest risk in the first few years after initial
infection.(5) However, the reactivation risk is about 10% per year in HIV-infected
persons.(8) in patients with impaired immunity, such as individuals with HIV. Recent
research suggests that the binary division between latent and active disease states may be
overly simplistic, and that many patients may exist on a spectrum between latent and
active disease.(5)
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Active TB manifests most commonly as pulmonary infection, resulting in cough with
sputum production and/or hemoptysis. However, TB can cause disease in almost any
body tissue, manifesting with organ-specific symptoms. Additionally, the disease often
causes constitutional symptoms, including fevers, night sweats, and severe weight loss.
Extrapulmonary and disseminated miliary TB is more common among HIV-infected
individuals. (9)

Tuberculosis Diagnostics:
TB control efforts are significantly hampered by the lack of accurate and rapid
diagnostics. For latent TB, the standard test for over a century has been Tuberculin Skin
Testing (TST), which relies on delayed-type hypersensitivity immune response to
mycobacteria placed intradermally.(10) However, the TST has several drawbacks. First,
it requires patients to return in 48-72 to read the result, which can result in a loss-tofollow-up, especially in hard-to-reach populations such as homeless individuals and
people who inject drugs and in resource-limited settings.(11) Secondly, TST can be
affected by receipt of the BCG vaccine, which is currently given to more than 90% of
children worldwide. Third, TST is not specific to TB and therefore can be positive in
response to mycobacteria other than tuberculosis (MOTT).(10)

In more recent years, a second test for latent TB has been developed, called the
Interferon-Gamma Release Assay (IGRA). This is a serum test that measures interferongamma release by T-cells in response to stimulation with the TB antigens ESAT-6 and
CFP-10. IGRA has several advantages over TST testing: it is more specific, not affected
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by prior administration of the BCG vaccine, and less affected by most environmental
mycobacteria. Additionally, it does not require a follow-up visit, which is advantageous
in hard-to-reach populations. The test is expensive, and requires access to a sophisticated
laboratory – a serious liability in resource constrained areas.(11) Although there is
evidence that it has high sensitivity in patients with active disease, it cannot distinguish
between latent and active TB.(5) IGRA’s cannot reliably distinguish between treated
prior infection and reinfection, and cannot be used to reliably predict who is at risk of
progressing to active disease.(12)

For active TB, culture of the organism is the most sensitive test, and is the current
diagnostic gold standard. Although liquid culture systems are preferable due to faster
turnaround time and higher yield, they are prohibitively expensive in many settings, and
solid agar is still widely used. Conventional drug susceptibility testing (DST) requires
culturing the organism. However, culture diagnosis takes a long time – even with the
newer automated liquid culture systems, diagnosis still takes a minimum of 10-15
days.(13) This is due to the extremely slow doubling rate of Mycobacterium tuberculosis,
which divides once every 15-20 hours.(5)

Most low and middle-income countries rely heavily on a combination of sputum smear
microscopy and chest x-ray for diagnosis.(5) For sputum smear microscopy, the
conventional Ziehl-Neelsen staining method was invented in the 1880s shortly after Koch
first discovered the bacterium.(2) Although the results for sputum smear microscopy are
relatively rapid, sensitivity ranges between 50 to 80%, and is subject to operator
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performance.(13) Additionally, HIV can further decrease the likelihood of smear-positive
TB.(14) The development of fluorescent microscopy with Auramine O increases the
sensitivity, and can increase the efficiency of microscopy.(15)

More recently, Nucleic Acid Amplification Tests (NAATs) have been developed for
active TB diagnosis. These tests are PCR-based, and offer many advantages to
conventional microscopy and culture. Cepheid has recently developed the GeneXpert
assay, which is a cartridge-based, automated test that can test for presence of
Mycobacterium tuberculosis and simultaneously test for rifampicin resistance. The test
can be performed with minimum laboratory expertise, and results can be available within
2 hours. In smear-positive patients, the assay has sensitivity of 98%. In smear-negative
patients, the assay has sensitivities of 72.5%, 85.1%, and 90.2% on one, two, and three
samples, respectively. Specificity is high at 99.2%.(16) In HIV-positive individuals, one
study found an Xpert sensitivity of 66.4% when screening patients eligible for
antiretroviral therapy in Ethiopia.(17) Among HIV-positive patients with a high clinical
suspicion for TB in Peru, sensitivity was high as 97.8%, with a specificity of 97.7%.(18)
The assay is also highly accurate for detection of rifampicin resistance, as long as the
predominant strain of bacteria present in the sample is rifampicin-resistant. The threshold
number of colony-forming units (CFUs) required for mycobacterial detection is much
lower than smear microscopy, similar to solid culture, but less than liquid culture. As
with any new technology, there are limitations. First, it cannot be used to monitor
response to therapy, as it will detect killed organisms. Second, it is very expensive.
Finally, although the turnaround time for diagnosis is significantly faster than for other
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methods of diagnosis, it is still not quite point-of-care, which can make same-day clinical
decisions difficult in crowded health facilities. Nevertheless, it represents a significant
advance for TB diagnosis.(16)

Tuberculosis Treatment:
For patients with active TB, the World Health Organization (WHO) recommends as firstline therapy a combination of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2
months, followed by rifampin and isoniazid for another 4 months. Since the early 1990s,
the WHO has endorsed Directly Observed Therapy (DOT) to improve medication
adherence and successful treatment completion.(19)

Unfortunately, the world has seen the emergence of drug-resistant strains of TB, which
are much more difficult to treat. Strains that are resistant to both rifampicin and isoniazid,
which often co-occur, are called Multi-Drug Resistant Tuberculosis (MDR-TB). For
MDR-TB, the WHO recommends using at least 4 drugs certain to be effective. The
groups of drugs are separated into 5 groups: first-line oral agents, injectable agents,
fluoroquinolones, oral bacteriostatic second-line agents, and 3rd line agents with unclear
role in the treatment of drug-resistant TB. Choosing the correct drug regimen can be
informed by DST testing for drugs that have good laboratory reliability, such as
injectable agents and fluoroquinolones. Alternatively, it can be based on survey data
showing rarity of resistance to the drug, or can be a drug that is not commonly used in the
area. MDR-TB treatment regimens last for a minimum of 18 months from the last
negative culture.(19)
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Most worryingly, strains resistant to even more drugs have emerged. A strain is called
“Extensively drug resistant” (XDR-TB) if it is resistant to isoniazid and rifampin, plus
any fluoroquinolone and at least one of three injectable second-line agents. Therapy for
this category is complex, and outcomes are highly variable.(20)

TB antimicrobial therapy went through a period of innovation in the 1940s-1960s.
However, as TB became a less urgent threat in the developed world, drug development
stalled. In the face of rising resistance, TB therapy has suffered from this lack of novel
therapeutics. However, recently a drug called bedaquiline was approved by the FDA for
TB treatment in 2012, the first new drug for TB in over forty years. Other agents are
currently in the drug development pipeline.(21)

Global Epidemiology
An estimated 2 billion people worldwide are latently infected with Mycobacterium
tuberculosis.(5) In the year 2013, there were an estimated 9.0 million new cases of active
TB, for an incidence of 126 per 100,000 population. The South-East Asia and Western
Pacific regions account for more than half (56%) of TB cases. About 1.1 million cases
(13%) were co-infected with HIV. Globally in 2013, there were about 1.5 million deaths
from TB, and 360,000 (24%) of these were co-infected with HIV.(22)

The African region is suffering the worst burden of disease. Although the region only
accounts for about a quarter of total incidence cases in 2013, it has the highest prevalence
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(300 per 100,000) incidence (280 cases per 100,000), and mortality (32 per 100,000
among HIV/TB coinfected people, and 42 per 100,000 excluding that group). The
African region also has the highest proportion of TB cases (34%) that are co-infected
with HIV.(22)

Globally, an estimated 5% of TB cases are estimated to be MDR-TB. Among new TB
cases in 2013, the estimated proportion of MDR-TB cases was 3.5%. Trend analysis
shows that the overall proportion of MDR-TB cases has not changed between 2008 to
2013, staying at about 3.5%. However, some countries have serious MDR-TB epidemics.
These include many countries of Eastern Europe. In Belarus, for example, an estimated
35% of new TB cases are MDR-TB, and an estimated 55% of cases undergoing
retreatment are MDR-TB. More than half the global burden of MDR-TB is in three
countries: India, China, and the Russian Federation.(23)

XDR-TB was first described in 2006, after an alarming report by Gandhi and colleagues
of an XDR-TB epidemic in the town of Tugela Ferry in the province of KwaZulu-Natal,
South Africa, where 53 of 1539 (6%) patients were found to have XDR-TB over a 1-year
period. Fifty-two of these patients died, 70% in the first 30 days after sputum
collection.(24) Since this report, 100 countries have reported at least one XDR-TB case
as of 2013.(23)

As discussed above, the largest risk factor for TB is HIV, which greatly increases
susceptibility to infection, primary progressive disease, reactivation, and recurrence.
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Other risk factors include diabetes, malnutrition, overcrowded living conditions,
smoking, indoor air pollution, silicosis, alcohol, and immunosuppressive drugs, such as
corticosteroids and TNF antagonists.(5)

Certain social groups have been historically associated with TB, especially in countries
where the disease is not endemic. In the USA, for example, these include people with a
history of homelessness(25), incarceration(26), or foreign-born from an endemic
country(27). Another major high-risk population is people who use illicit drugs.(28)

Tuberculosis in People Who Use Illicit Drugs:
Drug use is associated with both a higher prevalence of latent TB infection and higher
incidence of TB disease.(28-30) Drug users are more likely to be infectious, to take
longer to achieve negative culture, and to be at increased risk of mortality from TB. In
some studies, duration of injection drug use and older age were most commonly
associated with latent TB. There is also evidence of increased rates of transmission
among drug users, and there have been outbreaks among people who use drugs in many
countries around the world. (28)

Drug use was described as a risk factor for TB even before the HIV era, in a study by
Reichman and colleagues based in New York City in the 1970s.(31) One potential
explanation for this association is from the immunosuppressive effects of certain illicit
drugs. For example, opiates may directly impair the cell-mediated immune response.
Additionally, drug use is associated with other behaviors and risk factors that overlap
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with TB, including tobacco use, homelessness, alcohol abuse, and incarceration.
Additionally, crowded venues for drug use with poor ventilation may serve as sites of
transmission. TB outbreaks have also been associated with sharing drug equipment, and
the practice of “shotgunning” (inhaling and exhaling smoke directly into another’s
mouth).(28)

Studies show mixed results on whether people who inject drugs (PWID) have an
increased risk for latent TB over non-injectors. However, PWID are at increased risk of
HIV from needle-sharing based transmission, and this confers a significantly increased
risk of active TB disease. HIV-infected PWID may even be at increased risk of TB
infection and disease compared with other HIV-infected individuals.(28)

In addition to this TB risk, PWID are at increased risk for many poor health outcomes,
including viral hepatitis, bacterial soft tissue infections, infective endocarditis, and
overdose.(32, 33) PWID worldwide are estimated to have a 14.7 times the mortality risk
of the general population.(32)

For all of these reasons, PWID are an important target group for medical and public
health services. However, due to many barriers including social stigma, unstable
lifestyles, lack of health insurance, worries about narcotic withdrawal, poor knowledge of
TB transmission, and provider perceptions, PWID have been a hard-to-reach population
for most health systems.(28)

	
  

	
  

15	
  

Tuberculosis Case Finding:
Surveillance for active TB relies largely on passive case finding, in which symptomatic
patients present to healthcare sites for evaluation of disease.(34) The benefits of
community-based population screening for active TB is debated, with studies showing
mixed results on improvement in community TB prevalence.(35-37) However, passive
case finding may be insufficient for certain high-risk groups, in whom TB burden is
particularly high, or who do not regularly interface with the health system by their own
volition. The WHO has strong recommendations to systematically screen households and
other close contacts of TB cases, people living with HIV, and people with workplace
exposure to silica. WHO also conditionally recommends screening prisoners, people
living in high prevalence areas, and populations with poor access to healthcare, including
homeless people, people living in urban slums or remote areas, and other vulnerable or
marginalized groups.(34)

For the reasons specified above, people who use drugs are another group in whom active
case finding can be beneficial. The WHO issued recommendations in 2008 for
collaborative TB and HIV services for drug users. They recommend that all services
dealing with drug users have a case-finding protocol for TB and HIV. At a minimum, the
WHO recommends including a simple set of questions on the symptoms and signs of TB
as a basis for active case finding at facilities providing services to drug users.(38)
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Programmatically, different active case finding programs choose whether to start with a
symptom screen or to screen all program participants with chest radiography or sputum
collection. Symptom screens are simpler and cheaper to implement, but risk missing
asymptomatic cases. Similarly, programs have to choose whether to limit to sputum
smear analysis versus also culturing all collected sputum specimens. Sputum smear is
cheaper and requires less trained personnel than culture, but using smear microscopy
alone risks missing smear-negative TB. Culture is also required for drug susceptibility
testing to detect drug-resistant TB. The best protocol for active case finding is debated,
and often comes down to a decision based on local factors, such as available funding,
laboratory capacity, and prevalence of HIV. (34, 39) For the purposes of determining
isoniazid preventive therapy (IPT) eligibility among people living with HIV in resourceconstrained settings, the WHO recommends symptom-based case finding at facilities,
with the absence of four key symptoms enough to rule out active TB.(40) This conclusion
was based on a study by Getahun and colleagues in 2010 that found the absence of
current cough, fever, night sweats, and weight loss can identify a subset of people living
with HIV who have a very low probability of having active TB.(41)

Tuberculosis in Tanzania:
Tanzania ranks 18th out of the	
  22	
  countries	
  that	
  have	
  been	
  labeled	
  high-‐burden	
  countries	
  
by	
   the	
   WHO.	
   Together,	
   these	
   countries	
   account	
   for	
   80%	
   of	
   the	
   world’s	
   TB	
   cases.	
   In 2013,

the World Health Organization (WHO) estimated TB prevalence in Tanzania of 85,000
(172 per 100,000) and an incidence of 81,000 (164 per 100,000), with 1.1% of new cases
being multi-drug resistant (MDR). Significantly,	
   37%	
   of	
   the	
   tested	
   TB	
   patients	
   are	
   HIV-‐
infected.	
  As	
  the	
  first	
  African	
  country	
  to	
  implement	
  Directly	
  Observed	
  Therapy	
  (DOTS)	
  under	
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the	
   WHO,	
   Tanzania	
   has	
   a	
   relatively	
   well-‐developed	
   infrastructure	
   for	
   TB	
   treatment,	
   with	
  
treatment	
   success	
   rate	
   of	
   90%.	
   Despite	
   this,	
   there	
   is	
   an	
   annual	
   mortality	
   of	
   6000	
   HIV-‐
negative	
  TB	
  cases,	
  with	
  an	
  additional	
  mortality	
  of	
  6100	
  in	
  HIV/TB	
  coinfected	
  patients.	
  (22)	
  	
  
	
  

Drug Injection in Tanzania and Study Rationale:
East Africa has been an important stop along international drug trafficking routes for
three decades. The United Nations Office on Drugs and Crime (UNODC) predicts that
40-45 tons of Afghan heroin were trafficked to Africa in 2009, the majority entering East
African ports from Pakistan, Iran, the United Arab Emirates, and India. The trade appears
to be run by Nigerian traffickers, with heroin being transported through Nigeria before
being shipped to Europe. However, users in Africa consume an estimated 34 tons of
heroin, with only 7 tons being shipped onwards to Europe. UNODC estimated in 2011
that there are 1,736,000 heroin users in Africa, with approximately one-third residing in
Eastern Africa.(42)

In Tanzania, there were an estimated 200,000 – 250,000 individuals using heroin in
Tanzania, with approximately 40,000 injectors as of 2005.(43) The epidemics of TB and
human immunodeficiency virus (HIV) are particularly intertwined with heroin addiction
in Tanzania. While the 2012 estimate of HIV prevalence in the Tanzanian general
population was 5.1%(44), an estimated 42% of people who inject drugs (PWID) in Dar es
Salaam have HIV.(45)
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The Tanzanian AIDS Prevention Programme introduced methadone-based MedicationAssisted Treatment (MAT) in 2011 at Muhimbili National Hospital in Dar es Salaam,
Tanzania. The goal of the program was to address heroin addiction with the goal of
reducing injection drug use, preventing HIV, and helping those with HIV to engage in
care and treatment. This was the first public methadone clinic in sub-Saharan Africa, and
all clients were heroin injectors. Patients were referred to the MAT clinic by NonGovernmental Organizations (NGOs) that worked with PWID in the community.

In the first 4 months the clinic operated prior to our project, three patients had already
been diagnosed with pulmonary TB. One of these patients was hospitalized with severe
symptoms and ultimately died. This prompted significant concern that other patients
could have undiagnosed TB. The clinic staff was worried that these undiagnosed cases
could be lethal without early treatment, and could pose an infection risk to fellow patients
and healthcare workers.

Statement of Purpose
In response to concerns about undiagnosed TB in the patients of the MAT program at
Muhimbili National Hospital, we implemented an active case finding project for
pulmonary TB with the following goals:
1) To identify any undiagnosed pulmonary TB cases and link them to treatment
2) To assess the prevalence of active pulmonary TB in this population of PWID on
methadone treatment
3) To determine the prevalence of HIV/TB coinfection in this population
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4) To determine the proportion of cases with MDR-TB
5) To determine the proportion of cases that are smear-positive
6) To describe characteristics of TB cases

Methods:
Study Design:
This was a cross-sectional case finding study to determine the prevalence of active
pulmonary TB cases within a population of Tanzanian PWID on methadone treatment.
The primary outcome was to determine prevalence of active TB. Secondary outcomes
included prevalence of HIV/TB coinfection, prevalence of MDR-TB, and prevalence of
smear-positive TB.

Study Population and Recruitment:
The study was conducted at the Medically Assisted Treatment (MAT) program in the
Psychiatry Department at Muhimbili National Hospital, Dar es Salaam. Our study
population included all 222 registered patients who were regularly attending the MAT
program as of August 22nd, 2011, when enrollment concluded.

An informational flyer was posted outside the methadone-dispensing window several
days in advance of the study to inform patients of the upcoming screening. The
pharmacist directed patients to meet with study administrators on-site after receiving
methadone. Participants provided informed consent in Swahili prior to screening. Patients
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that were literate signed a consent form, and patients who could not write provided
fingerprints on the consent form, consistent with standard practices.

TB Case Finding Protocol:
A symptom-based questionnaire was adapted from a previous TB survey in Ethiopia, and
was administered to every consenting patient in Swahili by a native Swahili-speaker.
Patients were asked about the following symptoms: cough greater than 2 weeks duration
(with or without sputum, with or without hemoptysis), fever greater than 1 month
duration, night sweats, weight loss, and change in appetite. If the patient reported a cough
of less than 2 weeks duration, he or she was asked to return at 2 weeks duration to report
if the cough had persisted. In addition, patients were asked about past TB history,
housing and ventilation, and incarceration history (including pre-trial detention).

Any patient reporting one or more symptoms in the questionnaire was referred for
sputum collection (see Figure 1). Patients were asked to produce two sputum samples:
one was produced on-site after completion of the questionnaire and without exposure to
direct sunlight, while one was produced the following morning and delivered to clinic
staff when arriving for the patient’s methadone. Samples were stored indoors in a cool
environment out of direct sunlight for no longer than 12 hours. The study administrator
delivered these samples, without exposure to sunlight, to the Central Tuberculosis
Reference Laboratory located onsite at Muhimbili National Hospital.
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Figure 1: Flow Chart of Survey and Laboratory Testing Protocol

Total	
  MAT	
  Clients	
  
(222)	
  

Met	
  with	
  team	
  
(156)	
  
Consented,	
  	
  
Survey	
  Administered	
  	
  
(150)	
  
One	
  or	
  more	
  symptoms	
  	
  
(16)	
  

Did	
  not	
  meet	
  with	
  team	
  
(66)	
  

Did	
  not	
  consent	
  	
  
(6)	
  

AsymptomaJc	
  
(134)	
  

Sputum	
  smear	
  &	
  
culture	
  x	
  2	
  
Smear	
  PosiJve,	
  
Culture	
  PosiJve	
  	
  
(1)	
  

Smear	
  NegaJve,	
  
Culture	
  PosiJve	
  
(5)	
  

Drug-‐
SuscepJble	
  TB	
  
(5)	
  

Smear	
  NegaJve,	
  	
  
Culture	
  NegaJve	
  
(10)	
  

MDR-‐TB	
  
(1)	
  

MAT = Medication Assisted Treatment; TB = tuberculosis; MDR = multi-drug resistant.

Sputum smear analysis was performed by a trained technician using Auramine O
staining. Each sample was cultured using Lowenstein-Jensen solid media (Modified
Petroff Method). Culture-positive samples underwent Drug Susceptibility Testing (DST)
against isoniazid, rifampin, streptomycin, and ethambutol. Samples with suspected
Mycobacteria Other Than Tuberculosis (MOTT) were confirmed by rho-nitrobenzoic
acid (PNB).
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TB cases were defined as patients who had either smear or culture evidence of
Mycobacterium tuberculosis in at least one sputum sample. MDR-TB was defined as
resistance to isoniazid and rifampin.

Linking Cases to Treatment:
Clinicians at the MAT program were immediately informed of all patients with smear or
culture results positive for TB. These patients were referred to the National Tuberculosis
and Leprosy Programme (NTLP) at Muhimbili National Hospital, which prescribed their
therapy regimen according to national guidelines. Treatment was delivered on-site along
with methadone.

Chart Review:
As part of the MAT clinical program, patients have standardized assessments including
the Addiction Severity Index (ASI)(46) throughout the course of their treatment. The ASI
is a standardized instrument developed in 1980 by A. Thomas McLellan, used to
establish the nature and severity of possible medical, employment, drug, alcohol, legal,
family, social, and psychiatric problems. Each patient received a baseline ASI survey,
and monthly follow-up ASI surveys up to 3-months, at which point they were performed
as needed. A chart review of the ASI was used for demographic history, drug use history,
legal history, and living situation. If multiple ASI were present, information was taken
preferentially from the most recent follow-up ASI.
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Chart review was also performed for laboratory documentation of HIV status. HIVpositive status was defined by any prior positive HIV test, whether at the MAT clinic or
at another facility. HIV negative status was defined by a negative test at the MAT clinic
within the prior 3 months. All other patients were classified as unknown HIV status. For
patients not enrolled in our study, we collected basic demographic data from baseline
registration information and HIV status from laboratory record review.

Data Analysis:
Data was entered into Microsoft Excel and basic proportions were calculated in Excel. To
compare characteristics of enrolled vs. unenrolled patients, Stata was used to make
comparisons using two-sample student’s t-test for means and two-sample test for
proportions. P values < 0.05 were considered significant.

Ethical Approval
This study was cleared by two Institutional Review Boards: the Yale University Human
Investigations Committee granted an exemption, and the Muhimbili University of Health
and Allied Sciences Senate Research & Publications Committee granted ethical approval.

Role of the Student Author:
The student author generated the idea for the study in an initial meeting with his thesis
mentor, Dr. Bruce. He received an active case-finding questionnaire that had been
recently implemented by a public health student in Ethiopia, and adjusted it to fit the
Tanzanian setting. He then traveled to Dar es Salaam and worked with the Tanzanian
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AIDS Prevention Programme to translate the questionnaire into Swahili. He met with
clinicians, nurses, pharmacists, the Central Tuberculosis Reference Laboratory, and the
National Tuberculosis and Leprosy Programme to design and refine the protocol and
workflow. He was present for all patient interviews, and provided clarification and advice
to the Swahili-speaking interviewer as needed. He supervised the collection of sputum
specimens, and hand-delivered 90% of the samples to the laboratory. He performed all
chart review for patients enrolled in the study. Chart review for patients who were not
enrolled in the study was performed by a data manager at Pangaea Global AIDS
Foundation. He also implemented a protocol whereby the clinic could continue to screen
all of its future patients for TB upon registration. The student performed all data entry
and analysis, and wrote the manuscript, which was published in the International Journal
of Tuberculosis and Lung Disease in 2014.

Results
Recruitment:
From July 28 to August 22, 2011, 156 of 222 (70%) clients met with study
administrators, of whom 150 consented to this study. Table 1 compares age, sex, HIV
positivity rate, and prior history of arrest or charge between our sample and the 72
patients not enrolled in the study. Our sample was older than the unenrolled group (Mean
34.1 years vs. 31.5 years, p=0.002), and had a significantly higher percentage of known
HIV-positives (23% vs. 11%, p=0.03). There were no significant differences between
proportion of male patients and history of prior arrest or legal charge.
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Table 1: Baseline characteristics for all patients on methadone treatment as of August
22nd, 2011 at Muhimbili Medication Assisted Treatment Program, Dar es Salaam,
Tanzania
Characteristics

All registered
patients
(n=222)

Mean age in years
(SD)
Male
HIV-positive
Prior arrest or
charge

Enrolled
Un-enrolled
patients (n=150) patients (n=72)

p

33.3 (5.7)

34.1 (5.9)

31.5 (5.1)

0.002

204 (92%)
42 (19%)

139 (93%)
34 (23%)

65 (90%)
8 (11%)

0.54
0.03

138 (62%)

88 (59%)

50 (69%)

0.12

Note: all information taken from chart review.
IQR = Interquartile Range

Background characteristics:
Demographics, risk factors, and TB history of our sample are summarized in Table 2.
The median age was 34 years old, with an interquartile range (IQR) of 8. Men comprised
the largest group with 139 of 150 (93%) participants. Most patients were single (61%),
with a mean of 1.0 child. The majority of patients had been educated to a Primary (47%)
or Low Secondary (41%) level. All patients had a prior history of heroin injection, as this
was required for entry into the methadone program. In addition to heroin, marijuana
(36%) and alcohol (11%) were the 2 most common substances used. A majority of
patients (69%) reported staying with others, with a mean of 5 members per household. A
history of incarceration (including prison, jail, or pre-trial detention) was reported by 107
(71%) patients.

Chart review demonstrated 34 (23%) HIV-infected patients, and 12 (8%) HIV uninfected within the previous 3 months. Despite the elevated HIV risk among PWID, 104
(69%) refused HIV testing, and their status was unknown. A prior history of TB was
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reported by 26 patients (17%), and the median time since previous diagnosis was 5 years,
with an IQR of 5.5 years. The majority reported a history of pulmonary TB (73%), but
almost one-quarter (23%) had a history of extrapulmonary TB.

In their previous

diagnosis of TB, 14 (54%) patients reported diagnosis by laboratory methods, and an
additional 3 (12%) of patients were diagnosed by both laboratory methods and x-ray. No
laboratory or clinical data was available to confirm prior TB. Twenty-four (92%) patients
reported completing a full course of treatment, with 10 (38%) completing an 8-month
course and 14 (54%) completing a 6-month course. Only two patients (8%) reported a
history of defaulting on TB treatment. Most (81%) patients said that they had tested
negative after treatment, but 5 individuals (19%) said that they had never been tested
after beginning treatment.
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Table 2: Population demography, tuberculosis risk factors, HIV status, and tuberculosis
history of patients on methadone treatment at Muhimbili Medication Assisted Treatment
Program, Dar es Salaam, Tanzania

Characteristics
Median Age, IQR
Gender
Male
Female
Marital Status
Single
Married
Divorced/Separated
Widowed
Mean Number Children, SD
Education
No Education
Primary
Low Secondary
Upper Secondary
University
Additional Training*
Primary (Non-Heroin) Substance of Abuse
None
Alcohol
Sedatives, Hypnotics, Tranquilizers
Cannabis
Polysubstance
Housing
Own
Rent
Mean Rent TSH, SD
Staying with Others
Homeless
Mean Years in Same House, SD
Mean Number People, SD
Mean Number
Windows per Room
Previously Incarcerated or in Jail**
Knowledge about tuberculosis (1-5), SD***
Risk of tuberculosis (1-5), SD***
Effort to Prevent tuberculosis (1-5), SD***
	
  

34, 8

Non- tuberculosis
Patients
(n=144)
34, 8

Tuberculosis
Patients
(n = 6)
34.5, 6.25

93% (139/150)
7% (11/150)

92% (133/144)
8% (11/144)

100% (6/6)
0%

61% (92/150)
17% (25/150)
20% (30/150)
2% (3/150)
1.0, 0.9

62% (89/144)
16% (23/144)
20% (29/144)
2% (3/144)
1.0, 0.9

50% (3/6)
33% (2/6)
17% (1/6)
0%
1.0, 0.9

0.7% (1/150)
47% (70/150)
41% (62/150)
7% (11/150)
4% (6/150)
9% (13/150)

0.7% (1/144)
46% (66/144)
42% (60/144)
8% (11/144)
4% (6/144)
9% (13/144)

0
67% (4/6)
33% (2/6)
0%
0%
0%

47% (70/150)
11% (17/150)
4% (6/150)
36% (54/150)
2% (3/150)

47% (68/144)
10% (15/144)
4% (6/144)
36% (52/144)
2% (3/144)

33% (2/6)
33% (2/6)
0%
33% (2/6)
0%

11% (16/150)
19% (29/150)
37600, 25,700
69% (103/150)
1% (2/150)
12.0, 14.1
(n=148)
4.9, 2.6 (n=145)

10% (15/144)
20% (29/144)
37600, 25,700
68% (98/144)
1% (2/144)

17% (1/6)
0%
N/A
83% (5/6)
0%

12.0, 14.2 (n=141)

11.4, 13.1

4.9, 2.6 (n=139)

4.6, 2.7 (n=7)

1.5, 0.6 (n=148)

1.6, 0.6 (n=142)

1.16, 0.4

71% (107/150)
2.4, 1.0
1.8, 1.0
3.5, 1.2

71% (102/144)
2.4, 1.0
1.8, 1.0 (n=143)
3.5, 1.2

83% (5/6)
2.0, 0.6
3.5, 0.5
2.3, 0.5

Total Sample
(n = 150)

	
  

HIV Status
HIV Positive
HIV Negative
HIV Unknown
Previous History of tuberculosis
Years since Last Diagnosis (Median, IQR)
Type of tuberculosis, Most Recently
Pulmonary
Extrapulmonary
Not Sure
How Diagnosed, Most Recently
Laboratory Methods
X-ray
Laboratory and X-ray
Amount of Treatment, Most Recently
Complete, 8 months
Complete, 6 months
Incomplete, 5-6 months
Incomplete, <2 months
Total Completing Treatment
Total Defaulting on Treatment
Most Recent Test after Treatment
Positive
Negative
Not Tested after Beginning Treatment
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23% (34/150)
8% (12/150)
69% (104/150)
17% (26/150)
5.0, 5.5

22% (31/144)
8% (11/144)
71% (102/144)
16% (23/144)
5, 6.5

50% (3/6)
17% (1/6)
33% (2/6)
50% (3/6)
4.5, 2

73% (19/26)
23% (6/26)
4% (1/26)

74% (17/23)
26% (6/23)
4% (1/23)

67% (2/3)
33% (1/3)
0%

54% (14/26)
35% (9/26)
12% (3/26)

52% (12/23)
35% (8/23)
13% (3/23)

67% (2/3)
33% (1/3)
0%

38% (10/26)
54% (14/26)
4% (1/26)
4% (1/26)
92% (24/26)
8% (2/26)

43% (10/23)
57% (13/23)
0% (0/23)
4% (1/23)
96% (22/23)
4% (1/23)

33% (1/3)
33% (1/3)
33% (1/3)
0%
67% (2/3)
33% (1/3)

0%
81% (21/26)
19% (5/26)

0% (0/23)
83% (19/23)
17% (4/23)

0%
67% (2/3)
33% (1/3)

*All of these recorded one of the categories above as well as additional training.
** This data comes from administered questionnaire, and is not equivalent to “Prior Arrest or
Charge” from Table 1, which was taken from baseline Addiction Severity Index.
***Patients were asked to rate their knowledge of tuberculosis, risk of tuberculosis, and effort to
prevent tuberculosis on a scale of 1-5.
Acronyms: IQR = Interquartile range; SD = Standard Deviation; TSH = Tanzanian Shillings

TB Active Case-Finding:
Of the 150 surveyed, 16 (11%) had one or more symptoms and were referred for
laboratory testing (see Table 3). The sputum sample from 1 patient was AFB-positive on
sputum smear, and subsequently culture-positive. Culture of sputum samples from the
remaining 15 smear-negative patients revealed that 5 grew TB. Additionally, 1 patient
was found to have a Mycobacterium Other Than Tuberculosis (MOTT). On Drug
Susceptibility Testing (DST) of culture-positive cases, 1 patient was found to have MDR	
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TB. Of note, this MDR patient’s sputum was smear-negative. The sputum sample for 1
smear-negative, culture-positive patient was contaminated during DST. All patients
identified with TB had a cough greater than two weeks, producing sputum. Of the 13
patients reporting cough, 6 (46%) had TB. All patients who reported hemoptysis were
found to have TB.

Overall, 6 new cases of TB were identified in this active case finding program with a
prevalence of 4%, or 4000 per 100,000 (see Table 3). The demographics of those with
and without TB are presented in Table 2. Of importance, 5 patients with TB (83%) lived
with, on average, 4.6 other individuals. Additionally 5 patients (83%) had a history of
incarceration. Three patients were HIV-infected, while two were HIV-negative, with the
remaining patient having an unknown HIV status. Three of the patients reported a prior
history of TB; two of these (67%) reported completing the previous course of treatment,
while one defaulted from treatment.
Table 3: Tuberculosis laboratory testing results of patients on methadone treatment at
Muhimbili Medication Assisted Treatment Program, Dar es Salaam, Tanzania
Characteristic
(%)
n
Total Patients Surveyed
150
Symptom Positive
(11%)
16/150
Smear-Positive, Culture-Positive
(6%)
1/16
Smear-Negative, Culture-Positive*
(31%)
5/16
Smear-Negative, Culture-Negative
(63%)
10/16
Total New Cases
(4%)
6/150
(17%)
Multi-Drug Resistant**
1/6
*On sputum culture, one patient with an unknown HIV status was found to have Mycobacterium
Other Than Tuberculosis (MOTT). This patient was not considered a positive case, but may have
an opportunistic infection.
**One sputum sample was contaminated during DST.
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Discussion:
Our study met our goals by identifying undiagnosed pulmonary TB cases and link them
to treatment; assessing the prevalence of active pulmonary TB in this population;
determining the prevalence of HIV/TB coinfection; determining the proportion of cases
with MDR-TB; determining the proportion of cases that are smear-positive; and
describing characteristics of TB cases.

In our sample of 150 PWID on methadone maintenance, 4% (4000 per 100,000) had
active pulmonary TB. This is roughly 23 times the national Tanzanian TB prevalence of
172 per 100,000.(22) Of these 6 cases, 5 cases were smear-negative, and one smearnegative case had MDR-TB. To our knowledge, this study represents the first data on TB
in a population of PWID in Tanzania.

Our results have significant implications for TB control in this population. Tanzanian
PWID are a subpopulation at high risk for TB, and should be actively screened. If passive
case finding alone had continued, these individuals would have been undiagnosed for a
longer period of time, with potentially lethal consequences. With the high frequency of
cohabitation, these individuals were also at risk for infecting household contacts. As
methadone patients are required to attend the clinic 7 days a week, these undiagnosed
cases also presented a transmission risk to other MAT clients and their healthcare
providers. The original layout of the clinic’s waiting area lead to crowded conditions that
allowed for ample opportunity for airborne transmission. The high proportion of patients
with active pulmonary TB prompted the clinic staff to modify the structure of the waiting
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room to increase ventilation. Thus the program was beneficial for both cases and their
regular contacts, including patients and staff.

Comparison with other case finding and prevalence studies in Tanzania
Other Tanzanian studies on active TB have been performed in different populations with
varying rates of TB.(47-53) For example, Munseri and colleagues examined a cohort of
1318 subjects in 2 voluntary counseling and testing (VCT) centers in Dar es Salaam in
2002-2003. One of these VCT centers was based at Muhimbili National Hospital, the
same site where our study was implemented. Defining TB by both laboratory and clinical
criteria, TB was present in 101 (7.7%) subjects, of whom 38 (38%) were already known
TB cases and 63 (62%) were newly diagnosed. TB/HIV co-infection was detected in 70
(5.3%) of subjects. Limiting to laboratory-confirmed cases, 35 of 1280 (2.7%) of subjects
with an unknown TB status were culture-positive, which is slightly lower than our
microbiologically confirmed prevalence of 4%.(52)

Other studies have looked specifically at TB in HIV-positive populations in Tanzania.
For example, Peck and colleagues followed a cohort of 2514 HIV-positive adults starting
ART therapy at Bugando Medical Centre in Mwanza, Tanzania. Subjects did not have
evidence of TB at the beginning of the study, and had monthly screenings for 6 months
after starting ART. TB diagnosis was established by either microbiologic confirmation or
by symptoms and chest radiographic findings consistent with TB, along with a positive
response to anti-TB therapy. Although sputum smear microscopy was used, sputum
culture was not available. Of the 2514 cases, 72 (3%) subjects were diagnosed with TB,
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of which 66 (92%) subjects had pulmonary TB. Eleven (0.4% of cohort) subjects were
smear-positive, and the rest of the cases were smear-negative but had clinical criteria
consistent with TB.(48)

Comparison with other active TB studies in methadone clinics
Case finding studies for TB in methadone clinics have not been performed in Africa to
date; however, they have been performed elsewhere.(54-58) In the pre-HIV era of the
1970s, Reichman and colleagues surveyed PWID enrolled in 20 citywide clinics in the
New York City Methadone Maintenance Treatment Program. Subjects received TST for
latent TB, and TST-positive subjects were referred to the health department for clinical
evaluation and chest x-ray. Of 3818 subjects, 853 (22.5%) were TST-positive, and 52
(1.4%) had chest x-rays consistent with active TB.

After the advent of HIV in the late 1980s, Selwyn and colleagues prospectively studied
520 PWID enrolled in a methadone-maintenance program in the Bronx, New York. They
screened all subjects on admission for HIV and for latent TB with Tuberculin Skin
Testing (TST), and then followed them prospectively for development of latent TB or
active TB for a mean of 22 months. At baseline, 217 (42%) were HIV-positive, and fortynine of 217 (23%) HIV-positive subjects had a positive TST, compared to 62 of 303
(20%) HIV-negative subjects. Among those who had a negative PPD at the beginning of
the study, a conversion to positive PPD at follow-up was seen in 15 of 131 (11%) HIVpositive subjects and 26 of 202 (13%) HIV-negative subjects. These rates did not
significantly differ. However, the HIV-positive group was much more likely to develop
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active TB: eight of the 215 (4%) HIV-positive subjects developed active TB within the
follow-up period, and none of the HIV-negative group developed active TB. Among
those HIV-positive subjects who had a positive PPD at enrollment, 7 of 49 (14%)
developed active TB. Among our study’s 6 cases, 1 was HIV-negative in the last 3
months, and the other 5 were either HIV-positive or had an unknown status. (55)

More recently, Ruutel and colleagues studied a cohort of 112 PWID at a methadone
program in Estonia in 2007. They tested all eligible and consenting patients for HIV, and
for latent TB with TST and interferon-gamma release assay (IGRA). Of all subjects,
(86%) were HIV-positive, 17% were TST-positive, and 7.4% were IGRA positive. Of the
49 (43.8%) subjects who attended the TB clinic, none were diagnosed with active
TB.(58)

Recently, two papers from Iran studied PWID in methadone programs. From 2008 to
2009, Mamani and colleagues surveyed 268 PWID in methadone maintenance programs
in the city of Hamedan. About 30% of the subjects were HIV-positive. TST was
performed on all patients. For patients with positive TST, chest x-ray and sputum smear
microscopy was performed. TST was positive in 18.3% of subjects, and one case of
active TB was diagnosed by chest x-ray and sputum smear.(59) From 2011-2012,
Honarvar and colleagues surveyed 263 opiate users who attended university affiliated
drop-in centers, methadone maintenance clinics, and harm-reduction facilities in southern
Iran. About 75% were PWID, and the others were non-injectors. About 84% were on
methadone, and about 56% were HIV-positive. All received a symptom screen, and all
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symptomatic patients received sputum microscopy, sputum culture and chest x-ray. Three
(1%) culture-positive cases were found, two of which were smear-positive, and 1 of
which was in a PWID. The prevalence among PWID was 500 per 100,000, about oneeighth the prevalence in our study.(60)

Smear-Positivity:
In our study, 5 of 6 (83%) of the newly diagnosed cases were missed by sputum smear
and identified only by sputum culture. One potential explanation for this finding is that
HIV-infected individuals are more likely to have sputum-smear negative TB.(14) Two
studies among HIV-infected patients within Tanzania have shown smear sensitivity of
40%(53) and 61.8%(50). Of our 5 smear-negative, culture-positive patients, 2 were
known to be HIV-infected, and 2 had an unknown HIV status. Our results suggest that
sputum culture be included in all active screening programs of PWID. Of critical
importance, it took several weeks to reach a diagnosis for these smear-negative patients.
These patients continued to pose an infection risk during this diagnostic delay,
highlighting the need for rapid diagnostics in screening programs, such as the nucleic
acid-based testing. Due to these results, the MAT clinic plans to invest in a GeneXpert
array when resources are available.

Symptom Screen:
Our symptom analysis showed that cough greater than 2 weeks and sputum production
were the most sensitive symptoms, with all new diagnoses having these symptoms. This
is consistent with other studies, which have successfully used cough > 2-3 weeks as the
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only symptom screen.(61) At Muhimbili National Hospital, the same site where our study
was implemented, Mwita and colleagues surveyed 125 HIV-infected patients with cough
in 2006. Screening was sputum smear with Ziehl-Neelsen stain, but no culture was
performed. They found nine subjects (7.2%) with smear-positive TB.(47) This is similar
to 1 of 13 (7.7%) patients with cough in our study, although 6 of 13 (46%) were culturepositive, suggesting that Mwita and colleagues may have found more patients if they had
been able to culture sputum samples. Although cough greater than 2 weeks was 100%
sensitive among the patients tested in our study, our protocol did not identify
asymptomatic cases, so the sensitivity among the entire study population cannot be
calculated.

Characteristics of Population and TB Cases:
Our study found several interesting characteristics of TB cases. First, five out of
six patients with active TB in our sample lived with others, suggesting that household
contacts were at increased risk for transmission. A 2009 study by Kifai and Bakari from
Dar es Salaam found Mantoux skin test reactivity in more than 60% of household
contacts of smear-positive cases.(62) Another study by Ntinginya and colleagues used the
Cepheid Xpert MTB/RIF assay to conduct case finding among household contacts of TB
cases in Mbeya, Tanzania. Among 219 patients surveyed, the prevalence of active TB
was 2.3%.(63) The detection of at least one MDR-TB case in our sample makes the
potential for transmission beyond the PWID community even more worrisome.
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Additionally, there was a very high rate of past TB history in the population as a whole
(17%), and even higher among patients currently infected with TB (38%). There is
evidence of high rates of recurrent TB in Tanzania. For example, Lahey and colleagues
examined a cohort of 979 HIV-infected, BCG-immunized adults with CD4 counts >= 200
cells/uL who received placebo in a TB vaccine trial in Tanzania. Among 80 subjects who
reported prior active TB, 11 (13.8%) subsequently developed definite TB and 17 (21.3%)
definite/probable TB during a median follow-up of 3.2 years.(49) This is similar to our
rate of 11.5% (3 of 26).

In our study, a very high rate of patients had been previously incarcerated or held in pretrial detention (71%), which may have served as a major transmission site for PWID. A
study by Rutta and colleagues in the mid-1990s investigated prisoners at Bugando
Medical Centre in Mwanza, Tanzania which receives referrals from all ill prisoners at
nearby Butimba Prison. The investigators performed a chart review of all prisoners with
TB. Of 625 prisoners diagnosed with TB over a 3-year period, 501 cases had complete
patient records, of which 204 (40.7%) cases were smear-positive, suggesting a high
proportion of TB cases were infectious. This suggests that Tanzanian prisons may be a
high-yield site for case finding.

Limitations:
Our study has several limitations. First, our study used a small nonrandom sample, and
was susceptible to selection bias. Our sample had a significantly higher known HIVpositivity rate than unenrolled patients. There are two potential explanations. First, chart
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review was more thorough for patients in the sample, taking into account patient’s selfreport of positive status, while chart review for unenrolled patients was limited to
registration data and laboratory testing. Second, patients who refused or avoided
recruitment into our study may have also been more likely to refuse HIV testing, and may
have had undiagnosed HIV infection.

Another limitation was laboratory testing only symptomatic patients (with an emphasis
on pulmonary symptoms), missing asymptomatic cases and those with extra-pulmonary
TB. Although the study by Getahun and colleagues(41) mentioned in the introduction
showed that HIV-positive patients without the four key symptoms had a very low
probability of having active TB disease, some small studies in Tanzania have discovered
asymptomatic cases. For example, a prevalence study of 93 HIV patients in Dar es
Salaam by Mtei and colleagues found 4 of 14 cases had no symptoms or chest x-ray
findings consistent with TB.(51) In another study by Ngowi and colleagues of 233
patients in a rural Tanzanian HIV clinic, 75% of the 20 cases discovered had no
symptoms or chest x-ray findings consistent with TB.(53) Without data on these potential
asymptomatic cases, we could not calculate sensitivity and specificity of our screening
questions for the entire study population.

Third, 69% of the sample had an unknown HIV status, which limited our ability to
analyze rates of HIV-TB co-infection in this population. Fourth, the majority of our
patients were male, and our data provides limited insight into TB among female injectors.
This represents the gender distribution of the clinic as a whole, which had difficulty
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recruiting female injectors. Next, we defined a TB case as smear or culture positive
sputum – this may underestimate the TB prevalence in the MAT program in comparison
with national prevalence rates that include cases that are clinically diagnosed and not
microbiologically confirmed.
Finally, the scope of our study did not look at outcomes between patients identified by
passive vs. active case finding to observe an impact on mortality, which would be the true
sign of success of the screening program.

Future Steps:
This pilot study suggests high rates of active TB in PWID entering this methadone clinic,
and all future clients should be screened at entry, at a minimum using a symptom screen
with sputum smear and culture. If resources are found to conduct sputum testing on all
patients at registration, it may provide information on asymptomatic cases. The MAT
clinic has continued to screen patients with a symptom screen after the conclusion of this
project, and has found a substantially increased prevalence. Over 50 patients have
completed or are currently undergoing TB treatment along with daily methadone.
Treatment outcomes should be evaluated and improved.

Additionally, as our data showed that many TB cases lived with several other people,
future efforts should attempt contact tracing in the community. Household contact cases
should be linked to directly-observed treatment to decrease community transmission.
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Finally, the clients participating in the MAT program were selected based on their
motivation and likelihood to succeed in methadone treatment; therefore, it is reasonable
to believe that they represent a healthier subset of the larger PWID population, who may
have a higher burden of HIV and TB. Future studies should attempt case finding in the
community, potentially with the help of community-based NGOs and community
outreach vans run by the Tanzanian AIDS Prevention Programme.

Finally, as TB and HIV treatment were delivered together with methadone, treatment
outcomes should be studied to quantify benefits from this integrated approach to care for
PWID.

Conclusion:
In conclusion, this pilot study actively screened 150 people who inject drugs who were
started on methadone in Dar es Salaam, Tanzania and found that 6 patients had sputum
cultures indicative of active TB. This TB prevalence of 4% is 23 times higher than the
national prevalence of TB in Tanzania. Our study suggests sputum culture and DST
should be obtained on all patients with a cough greater than 2 weeks, productive of
sputum. Ongoing efforts to identify PWIDs with TB must be undertaken and effective
treatment programs must be established to assist patients in completing treatment
integrated with their methadone and antiretroviral therapy.
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